Argenica Therapeutics (ASX:AGN) — Material Events
ASX:AGN · 11 articles in the last 12 months · 100% assessed
Click a band to jump to that tier
Major ≥90
Significant 75–89
Notable 50–74
Routine <50
Not assessed
AI-Driven Analysis Uncovers ARG-007’s Breakthrough in Severe Stroke TreatmentHigh
AI Analysis Confirms ARG-007 Efficacy in Severe Stroke Patients, Paving Way for Targeted Phase 2b Trial
11 Dec 2025
·Clinical Trial Results Announcement
·85
Argenica’s ARG-007 Clears Key FDA Hurdle with Tenecteplase CompatibilityMedium
Argenica’s ARG-007 passes key FDA drug interaction test with tenecteplase, advancing stroke therapy development
4 Dec 2025
·ASX Announcement
·85
Argenica’s ARG-007 Shows Breakthrough Efficacy in Severe Stroke, Eyes Phase 2b TrialHigh
Argenica’s ARG-007 shows significant efficacy in severe stroke; plans Phase 2b trial and meets key FDA requirement
28 Jan 2026
·Quarterly Activities & Cashflow Report
·85
Argenica Clears Key FDA Genotoxicity Test, Paving Way for Phase 2b TrialMedium
Argenica clears key FDA genotoxicity test, advancing IND application for ARG-007
21 May 2026
·Regulatory Update
·85
Argenica Advances Late-Stage Stroke Trial with Clean FDA Safety Data and $6.35M CashMedium
Argenica advances late-stage stroke trial preparations with strong safety data and $6.35M cash reserves
24 July 2026
·Quarterly Activities and Cashflow Report
·85
Argenica Advances Phase 2b Stroke Trial With AI and Regulatory WinsMedium
Argenica advances Phase 2b stroke trial prep, secures EMA pediatric waiver, and reports $8M cash
29 Apr 2026
·Quarterly Activities and Cashflow Report
·80
Argenica’s ARG-007 Clears Safety Hurdle, Eyes Targeted Phase 2b Stroke TrialMedium
Argenica’s ARG-007 Phase 2 stroke trial meets safety endpoint, shows efficacy signals in high-risk subgroup; plans Phase 2b trial
31 Oct 2025
·Quarterly Activities & Cashflow Report
·80
Argenica Clears Final FDA Safety Hurdle for ARG-007, Eyes Phase 2b Trial StartMedium
Argenica completes final FDA safety assay for ARG-007, advancing clinical trial plans
11 June 2026
·Regulatory Update
·75
Argenica Secures EMA Paediatric Waiver, Fast-Tracking ARG-007 Stroke ApprovalMedium
Argenica secures EMA paediatric waiver for ARG-007 in stroke, accelerating European approval
2 Feb 2026
·Regulatory Update
·75
Argenica Boosts War Chest with $3.97M R&D Rebate Ahead of Phase 2b Stroke TrialMedium
Argenica secures $3.97M R&D tax rebate, advances Phase 2b stroke trial plans
17 Mar 2026
·ASX Announcement
·70
Argenica Therapeutics Posts $3.82M Half-Year Loss Amid Lower Revenue and Rising R&D CostsMedium
Argenica Therapeutics posts $3.82M half-year loss amid lower revenue and increased R&D spend
11 Feb 2026
·Appendix 4D Half-year report
·Unexpected
·70
No articles in this tier for the last 12 months.
Market Mentions
8
- appeared in market wrap coverage
These are market wrap articles where Argenica Therapeutics (ASX:AGN) was mentioned. They reflect broader market coverage, not company-specific announcements.
Healthcare Wrap - Week 30 (20 July -> 24 July) 2026
25 July 2026
Healthcare Wrap - Week 24 (8 June -> 12 June) 2026
13 June 2026
Healthcare Wrap - Week 21 (18 May -> 22 May) 2026
23 May 2026
Healthcare Wrap - Week 18 (27 Apr -> 1 May) 2026
2 May 2026
Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026
21 Mar 2026